Trial Profile
Phase 1 Dose-finding Study of Tumor-targeting Human Monoclonal Antibody-cytokine Fusion Protein L19TNFalpha Plus Melphalan Using Isolated Inferior Limb Perfusion in Patients With In-transit Stage III/IV Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Onfekafusp alfa (Primary) ; Melphalan
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Philogen
- 29 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Oct 2010 New trial record